300 results about "Sexually transmitted disease" patented technology

The invention relates to methods and products for preventing and / or treating sexually transmitted diseases. A nucleic acid and optionally an anti-STD agent, a birth control agent and / or a birth control device are administered, optionally in the context of a sustained release device to a subject to prevent or treat STD.

A microfluidic system for isolation and amplification of DNA or RNA from aqueous solutions and detection of the DNA or RNA on a lateral flow detection strip, including a disposable microfluidic card for use in analysis of bacteria in platelets and an analysis of sexually transmitted diseases (STD) in urine. The card will include an embedded membrane that filters out cells and cellular debris. Any biological debris on the membrane will be lysed and the DNA or RNA amplified via PCR amplification protocol, including appropriate reagents and thermal cycling conditions. The amplified DNA or RNA are transferred to a lateral flow detection strip for a visual diagnostic read out. An alternate embodiment includes a microfluidic card for use in typing antiglobulin assays.

A chemical composition, method and product for administration into the vaginal canal. The composition, method and product are effective in preventing the spread of sexually transmitted diseases, including the spread of AIDS.

An antiproliferative, antiinflammatory, antiinfective, immunization agent of a metal ion chelating agent such as picolinic acid, analogs or derivatives thereof, and methods of using the same. The agents chelate metals in metal containing protein complexes and enzymes required for growth, replication or inflammatory response. The preparations can be administered systemically or topically. The products can be used to reduce systemic levels of metals in disease states such as Wilson's disease, iron or lead toxicity. The preparations have antineoplastic, antiviral, antiinflammatory, analgesic antiangiogenic and antiproliferative effects and are used in the treatment of warts, psoriasis, acne, cancers, sunburn, inflammatory responses, untoward angiogenesis and other diseases and in the prevention of sexually transmitted diseases such as genital warts, herpes and AIDS.

It is the purpose of this invention to provide methods and systems for non-invasive deep brain neuromodulation using ultrasound for the treatment of anorgasmia, hypo-orgasmia, and for the production of orgasms (Orgasmatron). This can include impacting one or multiple points in a neural circuit to produce Long-Term Potentiation (LTP) or Long-Term Depression (LTD). The ultrasound transducers are attached at fixed positions on a holder. Use of ancillary monitoring or imaging to provide feedback is optional. Control of the ultrasonic transducers includes control of direction of the energy emission, intensity, frequency, and phase / intensity relationships to targeting and accomplishing up-regulation and / or down-regulation.

There is disclosed a method for treating dermatologic diseases caused by microbial overgrowth or inflammation, such as psoriasis, fungal infections, eczema, dandruff, acne, genital herpes lesions, and leg ulcers. There is further disclosed an antiviral lubricating composition that is effective in preventing the transmission of the HIV virus and other sexually transmitted diseases. There is also disclosed systemic and anti-inflammatory compositions and formulations and a method for reducing tissue inflammation in tissues such as the bowel, muscle, bone, tendon and joints (e.g., arthritis).

The present invention relates to a non-hormonal, biocompatible, and biodegradable intravaginal device for the delivery of spermiostatic, spermicidal and anti-infectious agents. The present invention also relates to methods of contraception using such a device, as well as the prevention and treatment of sexually transmitted diseases and vaginal infections through the application of the device.

The present invention is related to an intravaginal delivery system for the controlled release of drospirenone and an estrogen, optionally also comprising one or more therapeutically active or a health-promoting substance capable of giving and / or enhancing protection against bacterial and fungal infections, and / or enhancing protection against sexually transmitted diseases. The delivery system consists of one or more compartments, one of each comprising a core and a membrane encasing the core, said core and membrane essentially consisting of a same or different polymer composition, wherein at least one compartment comprises drospirenone ant at least one compartment which may be the same or different from the one comprising drospirenone, comprises an estrogen or a mixture of drospirenone and an estrogen, and wherein the membrane or the surface of the membrane or at least one of the cores comprises said therapeutically active or a health-promoting substance.

Compositions and methods of using thereof for the prevention of sexually transmitted diseases resulting from infection with one or more of viral pathogens have been developed. The compositions contain one or more porphyrins, tetrapyrrole macrocycle compounds with bridges of one carbon joining the pyrroles. In a preferred embodiment, the compositions are administered in a formulation suitable for administration to a mucosal surface.

An integrated multiplexed acoustic wave biosensor chip system with enhanced sensitivity has been developed. The biosensor system incorporates one or more microfluidic channels, coated with target-specific binding films enabling rapid and early detection of viral, bacterial or parasitic targets such as Dengue virus and sexually transmitted diseases in specimens from potentially infected patients. The biosensors are used in portable analytical systems that are suitable for real-time point of care (POC) clinical diagnosis in cost sensitive and / or resource limited settings. The highly sensitive biosensors utilize thinned single crystal piezoelectric substrates that propagate layer guided shear horizontal acoustic plate mode (LG-SH-APM) waves in sensing regions bearing immobilized binders that provide simultaneous and direct detection of mass changes due to multiple bound target pathogens or molecules.

The present invention is related to an intravaginal delivery system for the controlled release of drospirenone and an estrogen, optionally also comprising one or more therapeutically active or a health-promoting substance capable of giving and / or enhancing protection against bacterial and fungal infections, and / or enhancing protection against sexually transmitted diseases. The delivery system consists of one or more compartments, one of each comprising a core and a membrane encasing the core, said core and membrane essentially consisting of a same or different polymer composition, wherein at least one compartment comprises drospirenone ant at least one compartment which may be the same or different from the one comprising drospirenone, comprises an estrogen or a mixture of drospirenone and an estrogen, and wherein the membrane or the surface of the membrane or at least one of the cores comprises said therapeutically active or a health-promoting substance.

The present invention provides a synergistic topically applied personal hygiene product comprising 8 to 12% by wt. of Povidone-Iodine complex, 0.5 to 1.0% by wt. of potassium iodide, 1 to 10% by wt. of phosphate, 5 to 15% by wt. chlorhexidine acetate, 5 to 20% by wt. of alcohol, 1 to 5% by wt. of citric acid and the remaining being pharmaceutically acceptable excipients which provides disinfection against commonly known pathogens and prevents transmission of most of the sexually transmitted diseases and a process for preparing the same.

An improved two-layered condom device which offers improved sensation to the male wearer compared to a conventional condom, which should result in increased compliance with usage. The device provides a dual barrier, with lubricant between an inner condom and an outer condom which may contain a chemical or chemicals to neutralize bacteria, viruses, and sperm, thereby making it superior to a conventional single-layered condom in preventing unwanted pregnancy and the spread of sexually transmitted diseases.

Compositions, formulations, and methods for the treatment or prevention, or decreasing the frequency of transmission of a virus (such as human immunodeficiency virus type 1 (HIV-1), Herpes Simplex virus type 1 (HSV1), or Herpes Simplex Virus Type 2 (HSV2), or other virus), or a bacterial infection (such as Trichomonas vaginalis, Neisseris gonorrhoeae Haemopholus ducreyl, or Chlamydia trachomatis, or other bacterial species), or a fungal infection, using an anionic cellulose- or acrylic-based oligomer, polymer, or copolymer. The present invention also includes administering a therapeutically effective amount of said oligomer, polymer, or copolymer, or a pharmaceutically acceptable salt thereof, or with a pharmaceutically acceptable carrier or diluent, thereof. The invention relies on the unique biochemical substitution of the cellulose or acrylic backbone such that the resultant molecule can remain molecularly dispersed in solution (or gel or other formulation) and mostly dissociated over a wide range of physiological microenvironments, such as the low pH found within the vaginal lumen, preferably from a pH of 14 to below 3.5. These specific substitutions also impart on the resultant molecule potent antiviral, anti-bacterial, and anti-fungal properties. In addition, these compositions can be used as general disinfectants for human use such as in contact lens solutions, mouthwashes, toothpastes, suppositories, or as more generalized disinfectants found in soaps, household cleaning products, paints, water treatments modalities, or can be incorporated into cosmetic, and can be used as vehicles for drug delivery, an adjuvant in a therapeutic formulation, or as a preservative. These compounds can be delivered in a liquid or solid dosage form and can be incorporated into barrier devices such as condoms, diaphragms, or cervical caps, to help prevent the transmission of STDs. The compounds of this invention can also be used in combination therapies with other classes of antiviral, antibacterial, or antifungal agent having similar or differing mechanisms of action including, but not limited to, anionic or cationic polymers, copolymers, or oligomers, surfactants, protease inhibitors, DNA or RNA polymerase inhibitors (including reverse transcriptase inhibitors), fusion inhibitors, cell wall biosynthesis inhibitors, integrase inhibitors, or virus or bacterial attachment inhibitors.

Lubricant compositions and methods are disclosed for aiding and enhancing massage or sexual activity, treating and preventing sexually transmitted diseases, and preventing pregnancy by administering a colloidal metal containing composition. Colloidal metal containing compositions that include metal flakes, sperm-function inhibitors, antimicrobial agents, analgesics, plant extracts, anti-oxidizing agents, and anti-inflammatory agents are also provided and may advantageously be used to in the methods of the invention.

A garment includes a bifurcated body having front and rear sections wherein the front section is provided with a sheath oriented about a genital region and includes a ribbed outer surface. The rear section is provided with a plurality of apertures and is oriented about a buttock region respectively. The ribbed outer surface includes a plurality of protrusions. The apparatus further includes a mechanism for fastening the garment about the user's waist. A condom is positionable about a user's penis wherein a proximal end portion of the condom is engageable about the ribbed outer surface of the sheath, defining a frictional contact area for assisting to maintain the condom positioned about the penis during sexual activities.

A multi-function measurement condom includes an indicia that enables the user to accurately measure his penis in its erect state, while simultaneously aiding in the prevention of pregnancy and sexually transmitted diseases. The condom is comprised of a tubular-shaped sheath with at least an inner layer and an outer layer of an elastic material, a dome-shaped closed end, and an opposite open end. A protrusion on the sheath extends lengthwise, and an indicia is placed between the inner and outer layers of the sheath. This creates a dual length unit with two different scale marks positioned adjacently, and the indicia extending centrally over the elongated protrusion. The indicia are visible through the outer layer so that the proper measurement can be deciphered by an individual. A niche located on the inner layer of the sheath incorporates the long protrusion into the rest of the apparatus smoothly, and it extends from the tip of the condom to a point short of its open end.

The present invention provides compositions, devices and methods suitable for the increased sensitivity and selectivity of binding assays thereby reducing false positive results without little or no reduction in the detection of true positives. The present invention is based on the novel discovery that an oxidative agent in the context of the device of the present invention results in decreased false positive reactivity with little or no reduction in true positive reactivity. The devices, compositions and methods of the present invention may be used, for example, to detect pathogens giving rise to endogenous urine antibodies include those organisms known to be causative agents in sexually-transmitted diseases and other diseases. The devices and methods of the present invention are also useful for various diagnostic procedures.

An inexpensive, easily available, and convenient method of treating or preventing a virus infection is provided. The present invention relates to a method for the treatment or prevention of virus infections using polybiguanide-based compounds administering a therapeutically effective amount of a compound or a pharmaceutically acceptable salt thereof. The invention relies on the unique biochemical reaction in which polybiguanide-based compounds interfere with the spread of virus within or between organisms. The compositions and formulations described in the present invention are effective means to reduce the infectivity of the human immunodeficiency virus type 1 (HIV-1), and human herpes simplex viruses, and also to kill the causative organisms of many other sexually transmitted diseases (STDs).

The present invention discloses methods, primer, probes, and kits for genotyping various mutations or disease-causing agent. In one embodiment, the present invention is applied to detecting the presence of multidrug-resistant Mycobacterium tuberculosis, HBV, beta-globin mutations, mutations related to thrombophilia, or the presence of sexually transmitted diseases in a subject.

Means of easy manufacture and deployment of condoms are provided. A practical and inexpensive adhesive condom is achieved to augment user satisfaction, provide increased barrier protection and contraceptive efficacy. Compression to the penis is reduced, thereby facilitating the ease of attaining and maintaining erection, improving barrier protection and preventing the transmission of sexually transmitted diseases, as well as increasing utilization rates by enhancing sensation.

To identify molecular determinants of lytic bone disease in multiple myeloma, the expression profiles of ˜12,000 genes in CD138-enriched plasma cells from newly diagnosed multiple myeloma patients exhibiting no radiological evidence of lytic lesions (n=28) were compared to those with ≧3 lytic lesions (n=47). Two secreted WNT signaling antagonists, soluble frizzled related protein 3 (SFRP-3 / FRZB) and the human homologue of Dickkopf-1 (DKK1), were expressed in 40 of 47 with lytic bone lesions, but only 16 of 28 lacking bone lesions (P<0.05). DKK1 and FRZB were not expressed in plasma cells from 45 normal bone marrow donors or 10 Waldenstrom's macroglobulinemia, a related plasma cells malignancy that lacks bone disease. These data indicate that these factors are important mediators of multiple myeloma bone disease, and inhibitors of these proteins may be used to block bone disease.

The invention discloses a gel composition for vagina, containing buffering agent, bioadhesive polymer, water, phase transition temperature regulator and one or more poloxamer of poloxamer 237, poloxamer338 and poloxamer407. The weight percentage of the poloxamer is 15-30 percent, the weight percentage of the phase transition temperature regulator is 1.5-6.75 percent; the weight ratio of the poloxamer and the phase transition temperature regulator is 20:1-20:9; and the pH of the composition is 3.0-5.5. The invention also discloses a preparation method of the gel composition and the application of the gel composition in preparing conception control preparation, vagina lubricant, preparation or medicament for preventing sexually transmitted diseases or medicaments for preventing gynecological diseases. The gel composition for vagina is liquid under room temperature and is semi-solid in vagina, is convenient to prepare and use, has the pH value similar to the vagina environment and has better acidic buffering capability and viscosity without damaging the vagina.

Antimicrobial and contraceptive compositions and methods which prevent and / or reduce the risk of transmission of sexually transmitted diseases through sexual activity as well as prevent and / or reduce the risk of pregnancy are provided. The compositions contain (1) a matrix-forming agent, (2) a bio-adhesive agent, (3) a buffering agent, (4) optionally a humectant, (5) optionally a preservative, and (6) water; wherein the composition is suitable for application within the vagina; wherein the compositions form a semisolid matrix on contact with ejaculate (thereby trapping ejaculated microbes and spermatozoa); wherein the composition causes hardening of cervical mucus (thereby decreasing the probability of sperm entry); wherein the composition forms a bio-adhesive layer over vaginal surfaces (thereby preventing or reducing the risk of contact of STD-causing microbes with the vaginal surfaces); wherein the composition maintains an acidic vaginal pH of less than about 5 in the presence of semen ejaculated from the male; and wherein the composition does not significantly impair the natural microbiological balance within the vagina. The antimicrobial and contraceptive compositions may also contain additional antimicrobial and / or contraceptive agents (e.g., nonoxynol-9, octoxynol-9, benzalkonium chloride, phosphorylated hesperidins, sulfonated hesperidins, polystyrene sulfonates, substituted benzenesulfonic acid formaldehyde co-polymers, H2SO4-modified mandelic acids, povidone iodine, itraconazole, ketoconazole, metronidazole, clotrimazole, fluconazole, teraconazole, miconazole, tinidazole, iconazole, chloramphenicol, nystatin, cyclopiroxolamine, and the like).

Disclosed herein is the treatment of vision loss in a mammal by transplanting an effective amount of hNT-Neuron cells. The treatment can be accomplished by injecting the cells into the retinal area of the eye. Additionally, the cells can be injected into the visual cortex of the brain. Conditions to be treated are vision loss due to optic nerve damage, including glaucoma, optic nerve sheath meningioma and glioma, Graves' ophthalmopathy, benign or malignant orbital tumors, metastatic lesions, tumors arising from the adjacent paranasal sinuses or middle cranial fossa, giant pituitary adenomas, brain tumors or abscesses, cerebral trauma or hemorrhage, meningitis, arachnoidal adhesions, pseudotumor cerebri, cavernous sinus thrombosis, dural sinus thrombosis, encephalitis, space-occupying brain lesions, severe hypertensive disease or pulmonary emphysema.

Chemical compounds, being the alkyl sulfate of sulfated saccharides, particularly, dextrin, dextran, and cyclodextrin, and pharmaceutical compositions containing these compounds. The compounds of the invention provide antiviral activity, particularly in the treatment and prevention of sexually-transmitted diseases. Methods of treating viral infection and preventing viral transmission include administration include administration of the compounds of the invention orally, topically, subcutaneously, by muscular injection, by intraperitoneal injection and by intravenous injection.

The present invention provides a method and composition for treating pruritus, and also psoriasis which includes applying a compound of formula (I) in a suitable formulation to the affected area. Compounds of formula (I) can also be formulated as a vaginal cream to inhibit viruses such as HIV, and possibly prevent the transmission of other sexually transmitted diseases.

Disclosed herein is a drug delivery system consisting of one or more compartments and comprising a progestogenic compound dissolved in a thermoplastic polyethylene vinylacetate copolymer. Also disclosed are a contraceptive kit or hormone-replacement therapy kit comprising the drug delivery system, and a combination preparation that simultaneously provides contraception and treatment of a sexually transmitted disease comprising the drug delivery system.